TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05759923
Drug: OATD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
Study: NCT05120505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
Study: NCT06745076
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05470608
Drug: SL-1002
Normalized name: citric acid 1002 MG
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SL-1002 injectable solution
Study: NCT05470608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injectable solution
Study: NCT06372574
Drug: RO7617991
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study: NCT05803382
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05739435
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05894837
Drug: Hepatic Artery Bicarbonate Infusion
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatic artery bicarbonate infusion: once every four weeks
Study: NCT06431243
Drug: A group Purinostat Mesylate 8.4mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinostat Mesylate 8.4mg/m2 + EM 25mg
Study: NCT06431243
Drug: A group Purinostat Mesylate 11.2mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinostat Mesylate 11.2mg/m2 + EM 25mg
Study: NCT06431243
Drug: A group Purinostat Mesylate 15.0mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinostat Mesylate 15.0mg/m2 + EM 25mg
Study: NCT06431243
Drug: B group Purinostat Mesylate 6.0mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinostat Mesylate 6.0mg/m2 + Tislelizumab 200mg
Study: NCT06431243
Drug: B group Purinostat Mesylate 11.2 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
Study: NCT04867343
Drug: HR020602 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR020602 injection
Study: NCT04867343
Drug: fentanyl injection ； remifentanil injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl injection + remifentanil injection
Study: NCT06171789
Drug: PRO1107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of PRO1107
Study: NCT06435442
Drug: Epaminurad, Naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Epaminurad/ Period 2: Naproxen -\> Epaminurad+Naproxen
Study: NCT05102552
Drug: SPN-817, Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study: NCT05102552
Drug: SPN-817, Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study: NCT05102552
Drug: BIS-001, Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study: NCT06183931
Drug: ALXN2220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ALXN2220 via IV infusion.
Study: NCT06183931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo via IV infusion.
Study: NCT05650320
Drug: 0.3% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily administration for 4 weeks.
Study: NCT05650320
Drug: 1% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily administration for 4 weeks.
Study: NCT03260972
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
Study: NCT06343402
Drug: BBO-8520
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD
Study: NCT06717347
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT06717347
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06717347
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06734520
Drug: super-transplantation in 3 severe β -thalassemia pediatric patients.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
Study: NCT06740474
Drug: ABI-6250
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
Study: NCT06740474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
Study: NCT05176873
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study: NCT05176873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of placebo will be given.
Study: NCT06738342
Drug: CHX 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
Study: NCT04877821
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study: NCT06783829
Drug: SHR4394
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4394
Study: NCT06747312
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Study: NCT05906524
Drug: KD6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KD6001 will be administered intravenously.
Study: NCT05217927
Drug: Placebo comparator dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06786286
Drug: [14C]-ITI-1284
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
Study: NCT06784336
Drug: Iron chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100
Study: NCT06737146
Drug: MT027 cells suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study: NCT06482437
Drug: NMD670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken twice daily for 21 days
Study: NCT06482437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken twice daily for 21 days
Study: NCT06750458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
Study: NCT06571422
Drug: WJ47156
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
Study: NCT06577415
Drug: RAY1225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06578728
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25mg/mL intralesional injection into nail bed/nail matrix
Study: NCT06264531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
Study: NCT05063851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Study: NCT05792111
Drug: Trigger point injection (lidocaine)
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
Study: NCT05792111
Drug: Caudal epidural Group (bupivacaine + triamcinolone + NaCl)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
Study: NCT06581458
Drug: tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
Study: NCT06444178
Drug: REGN9933
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenous (IV)
Study: NCT06444178
Drug: REGN7508
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06748872
Drug: Lymphodepletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylcophosamide and Fludarabine
Study: NCT06748079
Drug: TQC3721 inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 is a target inhibitor.
Study: NCT06748079
Drug: Placebo for TQC3721 inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug substance.
Study: NCT06752044
Drug: Neoantigen-based peptide vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752343
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de
Study: NCT06752408
Drug: Aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
Study: NCT06749756
Drug: vitamin B6+ Vitamin B12 +vitamin C
Normalized name: folic acid / vitamin B12 / vitamin B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
Study: NCT06749756
Drug: vitamin B6+ Vitamin B12
Normalized name: folic acid / vitamin B12 / vitamin B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
Study: NCT06754865
Drug: Xiyanping injection+ antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiyanping injection+ antibiotic
Study: NCT06753565
Drug: Disease-modifying anti-rheumatic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
Study: NCT06752447
Drug: LNF2007
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Study: NCT06754943
Drug: Treatment A_Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT06754943
Drug: Treatment A_Period 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT06754943
Drug: Treatment B_Period 4
Normalized name: Acne Treatment 4 % - 5 % Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Study: NCT06754943
Drug: Treatment B_Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Study: NCT06753890
Drug: Changkang Granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Study: NCT06754644
Drug: QL2107
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg on day 1 of each 21-day cycle of the study
Study: NCT06738017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg oral tablet
Study: NCT06762730
Drug: Zoledronic Acid 5 mg/Bag 100 ml Inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolendric acid will be provided to HIV naïve patients with documented osteopnia
Study: NCT06763848
Drug: intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.
Study: NCT06767774
Drug: High intensity statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20mg
Study: NCT05677035
Drug: LINO-1713 1 tablet
Normalized name: ZINC OXIDE 24 g in 100 g TOPICAL CREAM [LINO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
Study: NCT05677035
Drug: LINO-1713 once a day for 24 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
Study: NCT06409819
Drug: phage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: phage therapy will consist of an individualized combination of lytic phages that are active against the participant's E. coli/K. pneumoniae isolates and will be administered intravenously twice daily for 7 days.
Study: NCT05222191
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
Study: NCT05222191
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
Study: NCT05222191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
Study: NCT05080569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3dd1 vaginal capsule
Study: NCT05939765
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
Study: NCT06387134
Drug: Conventional treatment with Western medicine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021.
Study: NCT06687980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study: NCT06124157
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT05019950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral tablet
Study: NCT06124157
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive IV
Study: NCT06124157
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive PO or IV
Study: NCT06124157
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive PO
Study: NCT06124157
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IT or IV
Study: NCT06124157
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive PO
Study: NCT05897320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT06270082
Drug: IK-595
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
Study: NCT06013644
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
Study: NCT00522158
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05810038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT06747455
Drug: BCG for Therapeutic Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
Study: NCT06747455
Drug: BCG for Therapeutic Use ( BI SAI JI )
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
Study: NCT05149326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
Study: NCT04147871
Drug: ADV7103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
Study: NCT04147871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules.